QCM
SPRY icon

Quantinno Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

Quantinno Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$814K Buy
101,412
+48,299
+91% +$463K ﹤0.01% 2337
2025
Q4 		$619K Buy
53,113
+12,641
+31% +$123K ﹤0.01% 2205
2025
Q3 		$407K Buy
+40,472
New +$581K ﹤0.01% 2198

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Quantinno Capital Management's SPRY Position: Q1 2026 in Review

Quantinno Capital Management increased its ARS Pharmaceuticals (SPRY) stake by 91% in Q1 2026, buying an estimated $463K and bringing the position to 101,412 shares worth $814K. The position accounts for ﹤0.01% of the portfolio, ranked #2337.

Quantinno Capital Management first reported a position in SPRY in Q3 2025 and has held it in 3 quarters since. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Quantinno Capital Management held 101,412 shares of ARS Pharmaceuticals worth $814K as of Q1 2026.
  • Quantinno Capital Management bought 48,299 ARS Pharmaceuticals shares in Q1 2026, an estimated $463K.
  • ARS Pharmaceuticals made up ﹤0.01% of Quantinno Capital Management's portfolio in Q1 2026, its #2337 holding.
  • Quantinno Capital Management first reported a position in ARS Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Quantinno Capital Management's 13F filing for Q1 2026, filed 15 May 2026.